Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* SCLC or PAC that is advanced or has spread to other parts of the body~* Treated with at least one other chemotherapy that did not work or where cancer relapsed~* Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1~Exclusion Criteria:~* Patients with cancer that spread to the brain~* Active, known or suspected autoimmune disease~* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC) (Type: ACTIVE_COMPARATOR): Small cell lung cancer (SCLC)
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC) (Type: ACTIVE_COMPARATOR): Pancreatic cancer (PAC)

Based on this trial design, predict the completion outcome and termination type (if applicable).